Claims for Patent: 6,514,529
✉ Email this page to a colleague
Summary for Patent: 6,514,529
| Title: | Oxazolidinone tablet formulation |
| Abstract: | The present invention provides a compressed tablet of an antibacterial oxazolidinone agent which provides high drug load and excellent bioavailability. |
| Inventor(s): | Ken Yamamoto, Homer Lin |
| Assignee: | Pharmacia and Upjohn Co |
| Application Number: | US09/809,696 |
| Patent Claims: |
1. A compressed tablet which contains: Linezolid 400.0 mg Corn starch 36.0-44.0 mg Microcrystalline cellulose 70.5-86.2 mg Hydroxypropylcellulose 7.2-8.8 mg Sodium starch glycolate 25.2-30.8 mg Magnesium stearate 5.04-6.16 mg. 2. A compressed tablet according to claim 1 which contains: Linezolid 400.0 mg Corn starch 36.0-44.0 mg Microcrystalline cellulose 70.5-86.2 mg Hydroxypropylcellulose 7.2-8.8 mg Sodium starch glycolate 25.2-30.8 mg Magnesium stearate 5.04-6.16 mg Opadry White YS-1-18202-A 11.2-22.4 mg Carnaba Wax 0-0.0224 mg 3. A compressed tablet according to claim 1 which contains: Linezolid 400.0 mg Corn starch 40.0 mg Microcrystalline cellulose 78.4 mg Hydroxypropylcellulose 8.00 mg Sodium starch glycolate 28.0 mg Magnesium stearate 5.6 mg 4. A compressed tablet according to claim 3 which contains: Linezolid 400.0 mg Corn starch 40.0 mg Microcrystalline cellulose 78.4 mg Hydroxypropylcellulose 8.00 mg Sodium starch glycolate 28.0 mg Magnesium stearate 5.6 mg Opadry White YS-1-18202-A 16.8 mg Carnaba Wax 0.0224 mg 5. A compressed tablet according to claim 1 which contains: Linezolid 600.0 mg Corn starch 54-66 mg Microcrystalline cellulose 105.84-129.36 mg Hydroxypropylcellulose 10.8-13.2 mg Sodium starch glycolate 37.8-46.2 mg Magnesium stearate 7.56-9.24 mg 6. A compressed tablet according to claim 5 where: Linezolid 600.0 mg Corn starch 54-66 mg Microcrystalline cellulose 105.84-129.36 mg Hydroxypropylcellulose 10.8-13.2 mg Sodium starch glycolate 37.8-46.2 mg Magnesium stearate 7.56-9.24 mg Opadry White YS-1-18202-A 16.8-33.6 mg Carnaba Wax 0-0.0336 mg 7. A compressed tablet according to claim 5 where: Linezolid 600.0 mg Corn Starch 60.0 mg Microcrystalline cellulose 117.6 mg Hydroxypropylcellulose 12.00 mg Sodium starch glycolate 42.0 mg Magnesium stearate 8.4 mg 8. A compressed tablet according to claim 7 where: Linezolid 600.0 mg Corn starch 60.0 mg Microcrystalline cellulose 117.6 mg Hydroxypropylcellulose 12.00 mg Sodium starch glycolate 42.0 mg Magnesium stearate 8.4 mg Opadry White YS-1-18202-A 25.2 mg Carnaba Wax 0.0336 mg 9. A method for providing blood levels of an antibacterial oxazolidinone by oral administration medically equivalent to the blood levels produced by IV administration of the same antibacterial oxazolidinone which comprises administration of a compressed tablet of the formulation: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, hydroxypropylcellulose, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc. 10. A method according to claim 9 where the antibacterial oxazolidinone is selected from the group consisting of linezolid, eperezolid and (S)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S,S-dioxide. 11. A compressed tablet according to claim 10 where the antibacterial oxazolidinone is selected from the group consisting of linezolid. 12. A method according to claim 11 where the compressed tablet contains: Linezolid 400.0 mg Corn starch 36.0-44.0 mg Microcrystalline cellulose 70.5-86.2 mg Hydroxypropylcellulose 7.2-8.8 mg Sodium starch glycolate 25.2-30.8 mg Magnesium stearate 5.04-6.16 mg 13. A method according to claim 12 where the compressed tablet contains: Linezolid 400.0 mg Corn starch 36.0-44.0 mg Microcrystalline cellulose 70.5-86.2 mg Hydroxypropylcellulose 7.2-8.8 mg Sodium starch glycolate 25.2-30.8 mg Magnesium stearate 5.04-6.16 mg Opadry White YS-1-18202-A 11.2-22.4 mg Carnaba Wax 0-0.0224 mg 14. A method according to claim 12 where the compressed tablet contains: Linezolid 400.0 mg Corn starch 40.0 mg Microcrystalline cellulose 78.4 mg Hydroxypropylcellulose 8.00 mg Sodium starch glycolate 28.0 mg Magnesium stearate 5.6 mg 15. A method according to claim 14 where the compressed tablet contains: Linezolid 400.0 mg Corn starch 40.0 mg Microcrystalline cellulose 78.4 mg Hydroxypropylcellulose 8.00 mg Sodium starch glycolate 28.0 mg Magnesium stearate 5.6 mg Opadry White YS-1-18202-A 16.8 mg Carnaba Wax 0.0224 mg 16. A method according to claim 11 where the compressed tablet contains: Linezolid 600.0 mg Corn starch 54-66 mg Microcrystalline cellulose 105.84-129.36 mg Hydroxypropylcellulose 10.8-13.2 mg Sodium starch glycolate 37.8-46.2 mg Magnesium stearate 7.56-9.24 mg 17. A method according to claim 16 where the compressed tablet contains: Linezolid 600.0 mg Corn starch 54-66 mg Microcrystalline cellulose 105.84-129.36 mg Hydroxypropylcellulose 10.8-13.2 mg Sodium starch glycolate 37.8-46.2 mg Magnesium stearate 7.56-9.24 mg Opadry White YS-1-18202-A 16.8-33.6 mg Carnaba Wax 0-0.0336 mg 18. A method according to claim 16 where the compressed tablet contains: Linezolid 600.0 mg Corn starch 60.0 mg Microcrystalline cellulose 117.6 mg Hydroxypropylcellulose 12.00 mg Sodium starch glycolate 42.0 mg Magnesium stearate 8.4 mg 19. A method according to claim 18 where the compressed tablet contains: Linezolid 600.0 mg Corn starch 60.0 mg Microcrystalline cellulose 117.6 mg Hydroxypropylcellulose 12.00 mg Sodium starch glycolate 42.0 mg Magnesium stearate 8.4 mg Opadry White YS-1-18202-A 25.2 mg Carnaba Wax 0.0336 mg 1. A compressed tablet which contains: 2. A compressed tablet according to claim 1 which contains: 3. A compressed tablet according to claim 1 which contains: 4. A compressed tablet according to claim 3 which contains: 5. A compressed tablet according to claim 1 which contains: 6. A compressed tablet according to claim 5 where: 7. A compressed tablet according to claim 5 where: 8. A compressed tablet according to claim 7 where: 9. A method for providing blood levels of an antibacterial oxazolidinone by oral administration medically equivalent to the blood levels produced by IV administration of the same antibacterial oxazolidinone which comprises administration of a compressed tablet of the formulation: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, hydroxypropylcellulose, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc. 10. A method according to claim 9 where the antibacterial oxazolidinone is selected from the group consisting of linezolid, eperezolid and (S)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazol idinyl]methyl]acetamide S,S-dioxide. 11. A compressed tablet according to claim 10 where the antibacterial oxazolidinone is selected from the group consisting of linezolid. 12. A method according to claim 11 where the compressed tablet contains: 13. A method according to claim 12 where the compressed tablet contains: 14. A method according to claim 12 where the compressed tablet contains: 15. A method according to claim 14 where the compressed tablet contains: 16. A method according to claim 11 where the compressed tablet contains: 17. A method according to claim 16 where the compressed tablet contains: 18. A method according to claim 16 where the compressed tablet contains: 19. A method according to claim 18 where the compressed tablet contains: |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
